John Johnson
John joined HealthQuest in 2023 as an Operating Partner focused on the Tactical Opportunities Fund. John is a recognized leader in the healthcare industry with more than three decades of experience across operating and investing. He is currently Chief Executive Officer at Reaction Biology, a global CRO. He previously was the Chief Executive Officer of Strongbridge Biopharma PLC. prior to the merger with Xeris Biopharma. John has held executive management roles at leading global corporations, including Johnson & Johnson, where he spent the majority of career and served as the Company Group Chairman of Biopharmaceuticals within Johnson & Johnson. He was responsible for the Johnson & Johnson Biotechnology, Immunology and Oncology commercial businesses. John also served as President of Eli Lilly & Company's Worldwide Oncology Unit, following the company's 2008 acquisition of Imclone Systems, Inc., where he served as Chief Executive Officer and a member of ImClone’s Board of Directors.
John has served on 18 boards and presently serves on 5 company boards including Reaction Biology, Axogen (AXGN), Xeris Pharmaceuticals (XERS), Verastem Oncology (VSTM) and Autolus Ltd (AUTL). He served on two private equity backed company boards through successful exits, including most recently BioAgilytix and W2O. He has also served as a member of the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA) and as a member of the Health Section Governing Board of Biotechnology Industry Organization (BIO). John received his BS from East Stroudsburg University and MBA from University of Rochester, Simon Business School. John and his wife have 4 children and 4 grandchildren. In his free time, he enjoys golf, fishing, and archery.
